2026 · 2nd Quarter (Apr 1 - June 30)

THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Filed by THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES).

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 20, 2026
Income: Not reported
Expenses: $2,120,000.00
Registrant: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Filing UUID: 960dfc23-83b5-4a7c-9c10-5504c089ad34
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Issues related to prior authorization.

PHA · Pharmacy

Issues related to PBM and drug pricing reform, health care transparency and affordability. P.L. 119-75 Consolidated Appropriations Act, 2026. Issues related to the specialty drug market.

DEF · Defense

Issues related to Tricare pharmacy issues.

HCR · Health Issues

Issues related to employer sponsored health insurance. Issues related to the No Surprises Act.

LBR · Labor Issues/Antitrust/Workplace

Issues related to competition in the health care marketplace.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.